•  
  •  
  •  
  •  

2025-12-01 08:31:56

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • South West Pinnacle becomes accredited prospecting agency to explore its own coal block in Jharkhand
  • Unified Data-Tech Solutions Ltd wins dual Industry Honours for Excellence and Integrity
  • GTPL Hathway Ltd launches its HITS Platform, 'GTPL Infinity' ushering in an era of Seamless Entertainment Delivery
  • Speciality Restaurants Ltd enters into franchise agreement for Asia Kitchen by Mainland China in UAE
  • Brigade Group Signs Joint Development Agreement for Premium Residential Project in Begumpet, Hyderabad

Keywords Selected:  ShilpaMedicare

IPO News

  • Shilpa Pharma Lifesciences Ltd to file for IPO

Stock Report

  • Shilpa Medicare Ltd receives 8 observations from USFDA for Unit 4 at Jadcherla
  • Shilpa Medicare Ltd allots 9,77,90,908 Bonus Equity shares
  • Shilpa Medicare Ltd receives initial authorization for Rivaroxaban Orodispersible Films from Europe
  • Koanna International FZ LLC and PPI Launch Joint Venture to Build New Pharma Manufacturing Facility in Saudi Arabia
  • Shilpa Medicare announces the approval of Nor Ursodeoxycholic Acid Tablets 500 mg for the treatment of Non‐Alcoholic Fatty Liver Disease in India
  • Shilpa Medicare Backs US Biotech Alveolus Bio to Accelerate Next‐Gen Lung Disease Therapies
  • EIR from USFDA, for Shilpa Medicare Ltd. Unit VI, Bengaluru.
  • Shilpa Medicare Ltd's Unit VI, Dabaspet, Bengaluru receives GMP Certification from SFDA, Saudi Arabia
  • Shilpa Pharma Lifesciences Limited, Unit-1, ANVISA Audit from Brazil
  • Shilpa Medicare announces Strategic Partnership with Orion Corporation for Recombinant Human Albumin for European Market
  • Shilpa Pharma Lifesciences Limited, Unit-1, Received EIR from USFDA
  • Europe (AGES, Austria) Inspection of Shilpa Biologicals Pvt Ltd
  • Shilpa Medicare Ltd enters into settlement agreement with Celltrion, Inc
  • Shilpa Medicare Ltd gets US approval for Varenicline Tablets, 0.5 mg and 1 mg
  • Amneal Pharmaceuticals launches 2nd NDA Bortezomib for injection3.5mg/1.4ml in US
  • Shilpa Biologicals Pvt Ltd signs strategic development partnership with mAbTree Biologics AG for a novel immunooncology asset
  • USFDA Inspection at Unit-1 of Shilpa Pharma Lifesciences Limited
  • Shilpa Pharma Lifesciences Limited, Received CEP from EDQM for API, Teriflunomide
  • Shilpa Medicare Ltd's Unit IV receives Eurasia GMP Approval
  • Europe GMP Certificate for Shilpa Medicare Ltd. Unit VII, Nacharam, Hyderabad from EMA, Austria
  • Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI
  • Indian Regulatory Authority - SEC approval for conducting Phase III Clinical trials for Recombinant Human Albumin (rHA) 20%
  • Shilpa Pharma Lifesciences Limited, received CEP from EDQM for API, Nifedipine
  • Shilpa Pharma Lifesciences Limited, Received CEP from EDQM for API, Octreotide

Latest Post

  • South West Pinnacle becomes accredited prospecting agency to explore its own coal block in Jharkhand
  • Unified Data-Tech Solutions Ltd wins dual Industry Honours for Excellence and Integrity
  • GTPL Hathway Ltd launches its HITS Platform, 'GTPL Infinity' ushering in an era of Seamless Entertainment Delivery
  • Speciality Restaurants Ltd enters into franchise agreement for Asia Kitchen by Mainland China in UAE
  • Brigade Group Signs Joint Development Agreement for Premium Residential Project in Begumpet, Hyderabad


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024